Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease
Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease
复制标题
DOI:
10.1053/j.gastro.2007.06.023
复制
发表时间:
2007-09-01
期刊:
影响因子:
29.4
通讯作者:
Rossi, Mauro
中科院分区:
文献类型:
--
作者:
Gianfrani, Carmen;Siciliano, Rosa A.;Rossi, Mauro
Background & Aims: Celiac disease is characterized by activation of HLA-DQ2/DQ8 -restricted intestinal gluten-specific CD4(+) T cells. in particular, gluten becomes a better T-cell antigen following deamidation catalyzed by tissue transglutaminase. To date, the only available therapy is represented by adherence to a gluten-free diet. Here, we examined a new enzyme strategy to preventively abolish gluten activity. MethodS: Enzyme modifications of the immunodominant alpha-ghadin peptide p56-68 were analyzed by mass spectrometry, and peptide binding to HLA-DQ2 was simulated by modeling studies. Wheat flour was treated with microbial transglutaminase and lysine methyl ester; ghadin was subsequently extracted, digested, and deamidated. Gliadin-specific intestinal T-cell lines (iTCLs) were generated from biopsy specimens from 12 adult patients with celiac disease and challenged in vitro with different antigen preparations. Results: Tissue transglutaminase-mediated transamidation with lysine or lysine methyl ester of p56-68 or gliadin in alkaline conditions inhibited the interferon gamma expression in iTCLs; also, binding to DQ2 was reduced but not abolished, as suggested by in silico analysis. Lysine methyl ester was particularly effective in abrogating the activity of gliadin. Notably, a block in the response was observed when iTCLs were challenged with gliadin extracted from flour pretreated with microbial transglutaminase and lysine methyl ester. Conclusions: Transamidation of wheat flour with a food-grade enzyme and an appropriate amine donor can be used to block the T cell.-mediated ghadin activity. Considering the crucial role of adaptive immunity in celiac disease, our findings highlight the potential of the proposed treatment to prevent cereal toxicity.